Who
Eugene Williams
Director
Company insider
Files Form 4 as: Chairman and CEO, ProMIS Neurosciences.
In numbers
- Trades disclosed
- 20
- Buys
- 9
- Sells
- 0
- Bought
- $318K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Jul 2022
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $49K2,000 at $24.40 | filing |
| 5 Mar 2026filed 6 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $49K2,000 at $24.40 | filing |
| 4 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $48K2,000 at $24.00 | filing |
| 4 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $48K2,000 at $24.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $22K1,000 at $21.89 | filing |
| 3 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $22K1,000 at $21.89 | filing |
| 2 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $23K1,000 at $22.53 | filing |
| 2 Mar 2026filed 4 Mar 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $23K1,000 at $22.53 | filing |
| 12 Jun 2025filed 16 Jun 2025 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 3 Oct 2024filed 7 Oct 2024 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 Dec 2022filed 19 Dec 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $4,6501,000 at $4.65 | filing |
| 16 Dec 2022filed 19 Dec 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $4,6401,000 at $4.64 | filing |
| 12 Dec 2022filed 13 Dec 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $5,0801,000 at $5.08 | filing |
| 7 Dec 2022filed 8 Dec 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $5,4901,000 at $5.49 | filing |
| 2 Dec 2022filed 6 Dec 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $5,9801,000 at $5.98 | filing |
| 11 Jul 2022filed 12 Jul 2022 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Bought | $9,8001,000 at $9.80 | filing |
News
No headline names them, or the companies they trade most, lately.